ESR1 and breast carcinoma: When stratified by the immunophenotypes, ctDNA positivity after NAT was associated with a significantly inferior RFS for ER(+) breast cancer or TNBC patients and a trend of higher recurrence rates for patients with the Her2 subtype (Figures 3A–C).